90Yttrium-ibritumomab tiuxetan: A novel treatment for non-Hodgkin's lymphoma

Expert Opinion on Biological Therapy

Volumn 4, Issue 8, 2004, Pages 1323-1331

  Blum, Kristie A ^b   Bartlett, Nancy L ^a  

^a USA   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

90Yttrium ibritumomab tiuxetan; Monoclonal antibody; Non Hodgkin's lymphoma; Radioimmunoconjugate; Radioimmunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; IBRITUMOMAB TIUXETAN; MONOCLONAL ANTIBODY; RADIOIMMUNOCONJUGATE; RITUXIMAB; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; YTTRIUM;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ASTHENIA; BLEEDING; BONE MARROW SUPPRESSION; BRAIN HEMORRHAGE; CANCER GRADING; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL TRIAL; COMPLEMENT DEPENDENT CYTOTOXICITY; DOSIMETRY; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESISTANCE; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; HUMAN; INFECTION; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RADIOIMMUNOTHERAPY; REVIEW; SECOND CANCER; THROMBOCYTOPENIA; VAGINA BLEEDING; ANIMAL; FORECASTING; IMMUNOLOGY; MOUSE; RADIATION DOSE; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; FORECASTING; HUMANS; IMMUNOCONJUGATES; LYMPHOMA, NON-HODGKIN; MICE; NEUTROPENIA; RADIOIMMUNOTHERAPY; RADIOTHERAPY DOSAGE; THROMBOCYTOPENIA; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 3442894823     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.8.1323     Document Type: Review

References (29)

1. MCLAUGHLIN P, GRILLO-LOPEZ AJ, LINK BK et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy of relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. (1998) 16:2825-2833. Pivotal trial of rituximab in low-grade NHL.
2. LEONARD JP, COLEMAN M, MATTHEW JC et al.: Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in non-Hodgkin's lymphoma. Blood (2002) 100:1388 (Abstract).
3. GAETANO ND, XIAO Y, ERBA E et al.: Synergism between fludarabine and rituximab revealed in follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br. J. Haematol. (2001) 114:800-809.
4. CHOW KU, SOMMERLAD WD, BOEHER S et al.: Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica (2002) 87:33-43.
5. CRAWFORD LM: New therapy for non-Hodgkin lymphoma. JAMA (2002) 287:1640.
6. GARBER K: Lymphoma market turf war imminent, pending Bexxar approval. Nat. Biotechnol. (2003) 21:115-116.
7. GARBER K: For Bexxar, FDA meeting offers long-awaited chance at approval. J. Natl. Cancer Inst. (2002) 94:1738-1739.
8. MULTANI P: Development of radioimmunotherapy for the treatment of non-Hodgkin's lymphoma. Int. J. Hematol. (2002) 76:410-410.
9. STASHENKO P, NADLER L, HARDY R et al.: Characterization of a human B lymphocyte-specific antigen. J. Immunol. (1980) 125:1678-1685.
10. 90Y-labelled anti-CD20 antibodies.
11. 90Y-ibritumomab tiuxetan in relapsed/refractory NHL.
12. WISEMAN G, WHITE CA, STABIN M et al.: Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur. J. Nucl. Med. (2000) 27:766-777.
13. WISEMAN G, KORNMEH E, LEIGH B et al.: Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: Combined data from 4 clinical trials. J. Nucl. Med. (2003) 44:465-474.
14. WITZIG TE, FLINN IW, GORDON LI et al.: Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J. Clin. Oncol. (2002) 20:3262-3269.
15. 90Y-ibritumomab tiuxetan in relapsed/refractory NHL.
16. WITZIG TE, GORDON LI, GASTON I et al.: 90Y-ibritumomab tiuxetan (Zevalin) radioimmunotherapy of follicular NHL: results by follicular subtype. Proc. Am. Soc. Clin. Oncol. (2002) 21:1063 (Abstract).
17. EMMANOUILIDES CE, SILVERMAN D, LEIGH B et al.: Successful treatment of Waldenstrom's macroglobulinemia with Zevalin-based therapy: a case report. Blood (2001) 98:4691 (Abstract).
18. WITZIG TE, GORDON LI, EMMANOUILIDES CE et al.: Safety and efficacy of Zevalin in four patients with mucosa associated lymphoid tissue (MALT) lymphoma. Blood (2001) 98:4746 (Abstract).
19. BARTLETT NL, WITZIG TE, GORDON LI et al.: 90Y-ibritumomab tiuxetan (Zevalin) radioimmunotherapy for transformed B-cell non-Hodgkin's lymphoma (NHL). Proc. Am. Soc. Clin. Oncol. (2002) 21:51 (Abstract).
20. GORDON LI, WITZIG TE, EMMANOUILIDES CE et al.: 90Y-ibritumomab (Zevalin) in aggressive non-Hodgkin's lymphoma: analysis of response and toxicity. Proc. Am. Soc. Clin. Oncol. (2002) 21:1061 (Abstract).
21. YOUNES A, PRO B, DELPASSAND E et al.: A Phase II study of 90Yttrium-ibritumomab (Zevalin) for the treatment of patients with relapsed and refractory mantle cell lymphoma (MCL). Blood (2003) 102:1461 (Abstract).
22. 90Y-ibritumomab tiuxetan.
23. ANSELL SM, RISTOW KM, HABERMANN TM et al.: Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. J. Clin. Oncol. (2002) 20:3885-3890.
24. WITZIG TE, WISEMAN GA, GEYER SM et al.: A phase I trial of two-sequential doses of Zevalin radioimmunotherapy for relapsed low-grade B-cell non-Hodgkin's lymphoma. Blood (2003) 102:1475 (Abstract).
25. EMMANOUILIDES C, MURRAY JL, VO K et al.: Earlier treatment with yttrium 90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy is associated with higher response rates and longer durations of response in patients with previously treated B-cell non-Hodgkin's lymphoma (NHL): results with second-line therapy. Blood (2003) 102:4949 (Abstract).
26. VOSE JM, BIERMAN PJ, LYNCH JC et al.: Phase I clinical trial of Zevalin (90Y-ibritumomab) in patient with B-cell non-Hodgkin's lymphoma (NHL) with relapsed disease following high-dose chemotherapy and autologous stem cell transplantation (ASCT). Blood (2003) 102:92 (Abstract).
27. COIFFIER B, LEPAGE E, BRIERE J et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N. Engl. J. Med. (2002) 346:235-242.
28. WINTER JM, INWARDS D, ERWIN W et al.: Zevalin dose-escalation followed by high-dose BEAM and autologous peripheral blood progenitor cell transplant in non-Hodgkin's lymphoma: early outcome results. Blood (2002) 100:1597 (Abstract).
29. NADEMANEE A, MOLINA A, FORMAN S et al.: A Phase I/II trial of high-dose radioimmunotherapy (RIT) with Zevalin in combination with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous stem cell transplant (ASCT) in patients with poor-risk or relapsed B-cell non-Hodgkin's lymphoma (NHL). Blood (2002) 100:679 (Abstract).